| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.44 | 3e-15 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.31 | 2e-12 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.49 | 2e-12 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.29 | 7e-11 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-10 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.43 | 3e-10 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.27 | 6e-10 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.32 | 8e-09 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.26 | 8e-09 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-08 |